Key facts
- This page summarizes Nathaniel Calloway's Form 4 filing for Anebulo Pharmaceuticals, Inc. (ANEB).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2024, 16:23.
Nathaniel Calloway - 13 Jun 2024 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)
- Reporting relationship
- Director
- Issuer ticker
- ANEB
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2024, 16:23:52 UTC
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 10 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nathaniel Calloway
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nathaniel Calloway filed Form 4 for Anebulo Pharmaceuticals, Inc. (ANEB) on 17 Jun 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANEB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +41,667
- Change %
- Price
- $0.000000
- Shares after
- 41,667
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,667
- Exercise price
- $2.10
- Footnotes
- F1
ANEB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,655
- Change %
- Price
- $0.000000
- Shares after
- 1,655
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,655
- Exercise price
- $2.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These stock options vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one year anniversary of the date of grant
Footnote F2
These stock options vest on the earlier of November 30,2024 or the date of the 2024 annual meeting of shareholders
SEC remarks
Exhibit List: Exhibit 24.1 - Power of Attorney (Nathaniel Calloway)